Skip to NavigationSkip to content

Business Services

Personalised medicine in oncology: Where are we now?

Published on 30/06/21 at 10:30am

The past decade has seen exponential growth in the field of oncology, with precision medicine at the forefront, driving positive change. Kat Jenkins takes a look at the world of precision medicine in cancer treatment, exploring the technologies and ideas that are shaping the way the healthcare industry is battling ‘the big C’

Novartis appoints Alessandra Dorigo as General Manager

Published on: 30/06/21

Alessandra Dorigo has been appointed as the new General Manager UK, Ireland, Baltics, and Nordics for Novartis Advanced Accelerator Applications (AAA).

Alessandra said: “In the word of Gandhi, you must be the change you wish to see in the world, which is why I am thrilled to be joining AAA and I look forward to returning to this field of healthcare where there are great unmet patient needs.

Exploring the potential of drug repurposing

Published on 30/06/21 at 10:24am

Drug repurposing is a little like recycling. It is the process of finding new therapeutic uses for drugs that already exist, rather than creating something new.

This makes drug repurposing an effective strategy to discover existing drug molecules with new pharmacological or therapeutic indications.

The drugs that can be repurposed range from substances that are already used for specific illnesses or conditions, old drugs that aren’t used anymore, drugs that didn’t meet their primary endpoint in clinical trials, and shelved drugs.

Biosimilars and Brexit: What’s in store for UK’s biosimilar market?

Published on 02/06/21 at 11:32am

It’s been 15 years since the first biosimilar entered the market, and the impact of these drugs on the healthcare industry has been immense. Now the UK has officially left the EU, what effect will Brexit have on the booming biosimilar market in the UK? Kat Jenkins takes a look at the new regulatory landscape post-Brexit, speaking with British Biosimilar Association’s Technical Director, Paul Fleming

The importance of representation in clinical trials

Published on 02/06/21 at 11:18am

Before any kind of new medicine can be made available to the market, it has to go through a strictly monitored development process. Only after passing strict safety and quality standards will a licence be granted.

In the UK, licences for new medicines are granted by the MHRA and the EMA, and will continue to be for two years post-Brexit.

Softbox brings in Sean Austerberry as new Director

Published on: 02/06/21

Softbox Systems has appointed Sean Austerberry as its Research and Product Development Director.

Sean will be responsible for all of Softbox’s global R&D, product development, and intellectual property management. He will lead the technical teams and work closely with sales and commercial to drive product strategy and deliver robust product roadmaps for future growth.

He said: “I’m delighted to join Softbox as part of the global leadership team and lead product R&D to support further business growth.

Sharp adds Robert O’Beirn to its Global Clinical Services Business

Published on: 02/06/21

Sharp has appointed Robert O’Beirn as SVP and Managing Director of its global Clinical Services business.

In early 2019 Mr O’Beirn joined the Sharp Senior Leadership team, serving as Managing Director of Sharp’s European Commercial Packaging business, as well as heading strategy and M&A for the division.

Debra Hussain new CCO of Acacia Pharma

Published on: 02/06/21

Acacia Pharma has appointed Debra Hussain as Chief Commercial Officer.

She is a highly experienced commercial leader having spent over 20 years at Eli Lilly in a range of roles.

CEO Mike Bolinder said: “I am so very pleased that we have been able to attract someone of her calibre and experience to join our executive team to fill the role I vacated almost two years ago when I assumed my current role as CEO.

Redx installs Natalie Berner as Non-Executive Director

Published on: 02/06/21

Redx Pharma has appointed Natalie Berner as a Non- Executive Director, she will represent RM Special Holdings 3 LLP on the board of directors.

Natalie brings extensive experience from the healthcare sector to the board. She is a Managing Director focusing on therapeutics at Redmile.

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches